Skip to main content
AlzChem Group AG logo

AlzChem Group AG — Investor Relations & Filings

Ticker · ACT ISIN · DE000A2YNT30 LEI · 8945004EL7WZK3ERG181 F Manufacturing
Open in API
Filings indexed 414 across all filing types
Latest filing 2022-05-05 AGM Information
Country DE Germany
Listing F ACT

About AlzChem Group AG

https://www.alzchem.com/en

AlzChem Group AG is a globally active, vertically integrated specialty chemicals company focused on NCN (Nitrogen-Carbon-Nitrogen) chemistry. Its production chain is based on raw materials such as calcium carbide and calcium cyanamide, from which it develops a wide range of products. The company serves diverse markets including human and animal nutrition, pharmaceuticals, agriculture, metallurgy, renewable energy, and automotive. Key products include high-purity creatine for dietary supplements (Creapure®), feed additives for animal nutrition (Creamino®), and high-purity guanidine salts used as intermediates for pharmaceutical and diagnostic applications, such as PCR tests. AlzChem also offers custom synthesis services and is a market leader in many of its business segments.

Recent filings

Filing Released Lang Actions
Annual General Meeting 2022 of Alzchem Group AG: Broad shareholder approval for growth course and dividend increase
AGM Information Classification · 98% confidence The document explicitly mentions 'Annual General Meeting 2022 of Alzchem Group AG' multiple times in the headline and body. It discusses shareholder approval, dividend increases, and the discharge of the Management Board, which are core activities of an AGM. Although it is presented as a news release (DGAP-News), the content is entirely focused on reporting the outcomes and key decisions made during the Annual General Meeting. Therefore, the most specific classification is AGM Information (AGM-R).
2022-05-05 English
Alzchem Group AG: Early contract extension with CSO Dr. Georg Weichselbaumer and COO Klaus Englmaier
Board/Management Information Classification · 99% confidence The document is a short news release dated May 2, 2022, announcing the early contract extension for the CSO and COO of Alzchem Group AG. It contains key personnel changes and brief commentary on business performance and strategy. This type of announcement, concerning changes in senior management, directly aligns with the definition of 'Board/Management Information'. It is not a full financial report (10-K, IR), an earnings release (ER), or a proxy statement (DEF 14A/PSI). Therefore, the appropriate code is MANG.
2022-05-02 English
Alzchem Group AG achieves record sales of EUR 129.4 million (+24%) in the first quarter of 2022
Earnings Release Classification · 100% confidence The document explicitly states it is reporting on the performance for the 'first quarter of 2022' and uses the keyword 'Quarterly / Interim Statement' in the DGAP header. It provides key financial highlights (sales, EBITDA, equity ratio) and an updated sales forecast for the full year. This content structure aligns perfectly with an Earnings Release (ER), which is the initial announcement of periodical financial results, or an Interim Report (IR), which is a comprehensive report for a shorter period. Since this document focuses on key highlights and an updated outlook, it fits the definition of an Earnings Release (ER) best, as it is an announcement summarizing the period's performance rather than the full, detailed quarterly report itself (which is often linked at the end, suggesting this is the press release version). The document length (7276 chars) is substantial but still functions as a summary announcement. Q1 2022
2022-04-28 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Veröffentlichung einer Stimmrechtsmitteilung' (Publication of a Voting Rights Notification) and explicitly details changes in share ownership and voting rights percentages (e.g., 'Stimmrechtsmitteilung', 'Erwerb bzw. Veräußerung von Aktien mit Stimmrechten', and section 6 showing the change from 12.03% to 15.05%). This directly corresponds to the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA), which covers official notifications regarding voting rights changes, distinct from general director dealings (DIRS) or general regulatory filings (RNS).
2022-04-25 German
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled 'Voting Rights Announcements' and contains detailed tables regarding the 'Notification of Major Holdings' under German Securities Trading Act (WpHG). It reports changes in voting rights percentages held by Morgan Stanley, crossing or reaching specific thresholds. This directly corresponds to the definition of a notification regarding changes in significant share ownership levels, which aligns best with the 'Major Shareholding Notification' category (MRQ). Although it mentions 'Voting Rights Announcements' in the header, MRQ is the specific regulatory filing type for reporting major holdings changes, whereas DVA is for reporting the *results* of a vote.
2022-04-25 English
Alzchem Group AG increases sales forecast for the fiscal year 2022
Earnings Release Classification · 100% confidence The document is a short announcement dated April 22, 2022, explicitly titled 'Alzchem Group AG increases sales forecast for the fiscal year 2022'. It discusses changes to the sales forecast for FY 2022, mentioning specific figures (up to EUR 520 million) and referencing the previous financial statements (as of December 31, 2021). This type of forward-looking guidance update, especially when issued outside of a standard quarterly or annual report filing, is typically classified as an Earnings Release (ER) if it contains key financial highlights, or sometimes as a Regulatory Filing (RNS) if it's a mandatory disclosure like an ad-hoc announcement under MAR (Regulation (EU) No 596/2014). Since it is a direct update to financial expectations (a key component of earnings/results communication) and is short, it fits best under Earnings Release (ER) as it provides the core financial news, even though it's a forecast change rather than final results. It is not a full report (10-K, IR), a presentation (IP), or a transcript (CT). Given the context of 'Ad-hoc' disclosure of forecast change, ER is the most appropriate fit among the provided options for financial performance updates. FY 2022
2022-04-22 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.